Litigation Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)
| Docket | ⤷ Subscribe | Date Filed | 2019-10-17 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 8,877,938; 9,388,134 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Details for Novartis Pharmaceuticals Corporation v. Alkem Laboratories Ltd. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-06-27 | 474 | Order - -Memorandum and Order | '938 Patent") and United States Patent No. 9,388,134 ("the '134 Patent") (collectively…Novartis 's patents related to its drug Entresto (sacubitril/valsartan), United States Patent No. 8,877,938… Asserted Patents"). (D.I. 372-2 at 2). On October 17, 2019, Novartis brought a patent infringement… Civil Action No. 20-md-2930-RGA PATENT LITIGATION NOV ARTIS PHARMACEUTICALS CORPORATION…x27;s ANDA products would infringe the Asserted Patents. (D.I. 11186-92, 300-01). | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
